The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients.
Robert Charles Doebele
Honoraria - Abbott Laboratories; Pfizer
Research Funding - ImClone Systems; Lilly; Pfizer
Dara L Aisner
Honoraria - GlaxoSmithKline; Pfizer
Anh T Le
No relevant relationships to disclose
Eamon M Berge
No relevant relationships to disclose
Amanda B. Pilling
No relevant relationships to disclose
Tatiana G. Kutateladze
No relevant relationships to disclose
Andrew James Weickhardt
Honoraria - Pfizer
Wilbur A. Franklin
No relevant relationships to disclose
Marileila Varella-Garcia
Honoraria - Abbott Molecular
D. Ross Camidge
Consultant or Advisory Role - ARIAD; Chugai Pharma; Novartis; Pfizer
Honoraria - Pfizer